miR‑29b is an indicator of prognosis in breast cancer patients

  • Authors:
    • Yoshiaki Shinden
    • Tomohiro Iguchi
    • Sayuri Akiyoshi
    • Hiroki Ueo
    • Masami Ueda
    • Hidenari Hirata
    • Shotaro Sakimura
    • Ryutaro Uchi
    • Yuki Takano
    • Hidetoshi Eguchi
    • Keishi Sugimachi
    • Yuko Kijima
    • Shoji Natsugoe
    • Koshi Mimori
  • View Affiliations

  • Published online on: May 12, 2015     https://doi.org/10.3892/mco.2015.565
  • Pages: 919-923
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

MicroRNA‑29b (miR‑29b) targets numerous important genes that mediate carcinogenesis and tumor development in breast cancer in vitro and in vivo. The aim of the present study was to determine the clinical significance of miR‑29b expression in primary breast cancer patients. Reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) of miR‑29b and certain target genes of miR‑29b, such as DNA methyltransferase 3A (DNMT3A), ten‑eleven translocation 1 (TET1) and thymine DNA glycosylase (TDG), was performed in 94 primary breast cancer samples. Low expression of miR‑29b in primary tumors was significantly associated with poorer disease‑free survival (DFS) (P=0.0075) and overall survival (OS) (p=0.0012). Multivariate analysis indicated that miR‑29b expression was an independent prognostic factor for OS [relative risk=15.6 (2.33‑348), P=0.0026]. In addition, a significant inverse correlation was identified between the expression levels of DNMT3A and miR‑29b in estrogen receptor‑positive breast cancer patients (P=0.027). To the best of our knowledge, this is the first study to investigate the clinicopathological significance of miR‑29b in breast cancer cases and miR‑29b is shown to act as a tumor suppressive microRNA in breast cancer and as a potential marker for recurrence and metastasis in breast cancer patients.
View Figures
View References

Related Articles

Journal Cover

July 2015
Volume 3 Issue 4

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Shinden, Y., Iguchi, T., Akiyoshi, S., Ueo, H., Ueda, M., Hirata, H. ... Mimori, K. (2015). miR‑29b is an indicator of prognosis in breast cancer patients. Molecular and Clinical Oncology, 3, 919-923. https://doi.org/10.3892/mco.2015.565
MLA
Shinden, Y., Iguchi, T., Akiyoshi, S., Ueo, H., Ueda, M., Hirata, H., Sakimura, S., Uchi, R., Takano, Y., Eguchi, H., Sugimachi, K., Kijima, Y., Natsugoe, S., Mimori, K."miR‑29b is an indicator of prognosis in breast cancer patients". Molecular and Clinical Oncology 3.4 (2015): 919-923.
Chicago
Shinden, Y., Iguchi, T., Akiyoshi, S., Ueo, H., Ueda, M., Hirata, H., Sakimura, S., Uchi, R., Takano, Y., Eguchi, H., Sugimachi, K., Kijima, Y., Natsugoe, S., Mimori, K."miR‑29b is an indicator of prognosis in breast cancer patients". Molecular and Clinical Oncology 3, no. 4 (2015): 919-923. https://doi.org/10.3892/mco.2015.565